Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...
Citi analyst Joanne Wuensch lowered the firm’s price target on Sight Sciences (SGHT) to $3 from $4.60 and keeps a Neutral rating on the shares. The firm adjusted medical technology models post the Q4 ...
) has been revised to $8.01 / share. This is an increase of 22.34% from the prior estimate of $6.55 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...
BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “relatively uneventful” besides an announcement for ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. If you are wondering whether Exact Sciences at around US$103 a share still offers ...
Leerink analyst David Risinger raised the firm’s price target on Roivant Sciences (ROIV) to $32 from $29 and keeps an Outperform rating on the shares. The firm cites higher long-term profitability ...
Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public offering at $21.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results